Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Neuland Laboratories Ltd Stock Analysis

Small Cap
Evaluated by 789 users | BSE: 524558 | NSE: NEULANDLAB |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 8.2%9.55%12.29%14.94%10.79%12.1%11.24%3.17%3.42%3.37%8.91%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 397448461466469510579527667763937949
Y-o-Y Gr. Rt.-13%2.8%1.1%0.7%8.7%13.5%-8.9%26.4%14.4%22.8%-
Adjusted EPS (Rs.) 6.29.6718.9936.5118.5429.3253.0713.8315.4813.0856.7756.80
Y-o-Y Gr. Rt.-56%96.4%92.3%-49.2%58.1%81%-73.9%11.9%-15.5%334%-
Book Value per Share (Rs.) 109.99130.84121.84151.75178.97206.3260.03273.54541.45549.21608.71625.32
Adjusted Net Profit 4.15.515.229.316.526.147.212.319.916.872.873
Net Op. Cash Flow (Rs. Cr.) 32.249.226.248.513.144.738.911.569.656.6189-
Debt to Cash Flow from Ops 7.264.478.053.9214.374.084.9427.713.334.580.9-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Neuland Laboratories Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 8.5%12.9%21.1%22.8%
Adjusted EPS 21.7%14.1%60.1%334%
Book Value per Share 18.624.230.610.8
Share Price 38.5% 11.7% 57.8% 53.7%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 5.747.3717.526.4511.6615.1412.972.243.182.49.799.21
Operating Profit Margin (%) 11.8711.413.1815.8914.3515.6618.459.619.4813.5215.8914.79
Net Profit Margin (%) 1.021.223.36.283.515.118.152.332.982.27.777.68
Debt to Equity 3.252.982.161.561.180.990.831.310.330.370.220.13
Working Capital Days 188187187211244233220284242225207206
Cash Conversion Cycle 57516073828710615212111610666
Loading price chart...
Entity Percentage Holding
Promoters 36.22%
Institutions 21.68%
Non-Institutions 42.10%
Pledged *4.344.354.354.314.304.304.304.304.304.30
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Neuland Laboratories Ltd's earnings have grown by 14.1%, whereas share price has appreciated 11.7% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.

Neuland Laboratories Ltd share price has appreciated 38.5% annually (CAGR) over the past ten years.

Data is not available for this company.

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.

It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.

Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.

It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.

Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.

Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.

The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.

Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Product range of the company includes:

  • Anti -Asthmatics
  • Fluoroquinolones
  • Cardiovascular
  • CNS
  • Corticosteroids
  • Anti-Ulcerant
  • Anti-Fungal
  • Anti-Parkinsons
  • Anti-Alzheimers

Achievements/ recognition:

  • Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
  • USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
  • Received cGMP clearance for both facilities from TGA, Australia in 2004.
  • Certificate of suitability for product itraconazole in 2006.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback